First multicenter study of modified release phosphatidylcholine "LT-02" in ulcerative colitis: a randomized, placebo-controlled trial in mesalazine-refractory courses
about
The intestinal microbiome, barrier function, and immune system in inflammatory bowel disease: a tripartite pathophysiological circuit with implications for new therapeutic directions[Microbiome and nutrition. The way to a future therapy for chronic inflammatory bowel diseases?].Blood Trimethylamine-N-Oxide Originates from Microbiota Mediated Breakdown of Phosphatidylcholine and Absorption from Small IntestineRevealing Potential Biomarkers of Functional Dyspepsia by Combining 1H NMR Metabonomics Techniques and an Integrative Multi-objective Optimization Method.Cosmc is an X-linked inflammatory bowel disease risk gene that spatially regulates gut microbiota and contributes to sex-specific risk.Clostridium Difficile Colitis in Trauma Patients - a Global Step by Step Review.Pathway-based approaches to the treatment of inflammatory bowel disease.Recent advances in understanding and managing Crohn's disease.Emerging treatments for ulcerative colitis: a systematic review.Emerging oral targeted therapies in inflammatory bowel diseases: opportunities and challengesGenetic and Transcriptomic Bases of Intestinal Epithelial Barrier Dysfunction in Inflammatory Bowel Disease.Surfactant inhibits ATP-induced release of interleukin-1β via nicotinic acetylcholine receptors.Placebo response and remission rates in randomised trials of induction and maintenance therapy for ulcerative colitis.Genetic Mouse Models with Intestinal-Specific Tight Junction Deletion Resemble an Ulcerative Colitis Phenotype.Phospholipase A2 of Microbiota as Pathogenetic Determinant to Induce Inflammatory States in Ulcerative Colitis: Therapeutic Implications of Phospholipase A2 Inhibitors.Proteomics and Lipidomics in Inflammatory Bowel Disease Research: From Mechanistic Insights to Biomarker IdentificationRecent advances and emerging therapies in the non-surgical management of ulcerative colitisEmerging Therapies for Inflammatory Bowel Disease
P2860
Q26745700-5AC3F4EB-19EA-4B13-8331-FAC5B1008AC4Q35207243-5BE91AB1-8511-44FF-93EA-E369702F1A4BQ36262624-54E77B3D-77F1-4B49-A50B-6CF3F2FDC334Q36442812-671B49BD-12B4-4821-A265-DB8174347D49Q37534378-319659A3-0050-464C-A0A4-51D909E4C82DQ37668965-EDB07298-7A36-4016-9D2D-77F303730746Q38593257-F4AE942E-D8CF-41C2-B370-B453002B73DDQ39121157-3E64455C-A14F-4DF4-B796-F6D12C534D29Q39306383-2877204B-CF9C-4DC1-9186-F8446E5C0403Q42375646-F3067A6D-3106-4E41-B8FC-5DB3A113E2F3Q47835525-77BD2C88-30C4-48D3-A083-41824134C315Q47917345-B92872C7-AEE2-42D4-A088-96FBD91E36D2Q47958039-D785BF8D-A9B1-4208-8859-18178740E043Q52838504-CCC62C47-FB3C-4B72-81A0-DBF9E105F39FQ55345070-5166CEC7-E50A-44FB-B9DF-58E25E38E8BDQ57156865-DCC3C851-E3CB-4BF3-AC50-9A2BB10B17A1Q57170397-5653D664-D526-4DF2-A727-98040F939F43Q58099968-BEA50EEF-3578-47C7-9036-E684A649ED98
P2860
First multicenter study of modified release phosphatidylcholine "LT-02" in ulcerative colitis: a randomized, placebo-controlled trial in mesalazine-refractory courses
description
2014 nî lūn-bûn
@nan
2014 թուականի Մայիսին հրատարակուած գիտական յօդուած
@hyw
2014 թվականի մայիսին հրատարակված գիտական հոդված
@hy
2014年の論文
@ja
2014年論文
@yue
2014年論文
@zh-hant
2014年論文
@zh-hk
2014年論文
@zh-mo
2014年論文
@zh-tw
2014年论文
@wuu
name
First multicenter study of mod ...... mesalazine-refractory courses
@ast
First multicenter study of mod ...... mesalazine-refractory courses
@en
type
label
First multicenter study of mod ...... mesalazine-refractory courses
@ast
First multicenter study of mod ...... mesalazine-refractory courses
@en
prefLabel
First multicenter study of mod ...... mesalazine-refractory courses
@ast
First multicenter study of mod ...... mesalazine-refractory courses
@en
P2093
P2860
P921
P356
P1476
First multicenter study of mod ...... mesalazine-refractory courses
@en
P2093
Andreas Kocjan
Carsten Schmidt
Frank Zuelch
Georg von Boyen
Gerhard Keilhauer
Limas Kupcinskas
Max Karner
Peter Uebel
Stefan Schreiber
P2860
P304
P356
10.1038/AJG.2014.104
P407
P577
2014-05-06T00:00:00Z